<button id="eiezk"><video id="eiezk"></video></button>

產(chǎn)品名稱

ABT 869 - Linifanib

產(chǎn)品貨號

Axon 1638 CAS [796967-16-3] MF C21H18FN5OMW 375.40 Purity: 99% Soluble in DMSO Description A multi-targeted receptor tyrosine kinase (RTK) inhibitor, targeting VEGRFs, PDGFRs, Fms-like tyrosine kinase-3 and c-KIT. In cellular assays ABT869 inhibits RTK phosphorylation (IC50 = 2, 4, and 7 nM for PDGFR-β, KDR, and CSF-1R, respectively) and VEGF-stimulated proliferation (IC50 = 0.2 nM for human endothelial cells) References Certificates Categories Extra info DH Albert et al. Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor. Mol. Cancer Ther. 2006, 5, 995-1006. ? J Zhou et al. ABT-869, a promising multi-targeted tyrosine kinase inhibitor: from bench to bedside. J. Hematol. Oncol. 2009, 2, 33. ? AK Ikeda et al. ABT-869 inhibits the proliferation of Ewing Sarcoma cells and suppresses platelet-derived growth factor receptor beta and c-KIT signaling pathways. Mol. Cancer Ther. 2010, 9(3), 653-60. Certificate of Analysis Material Safety Data Sheet Angiogenesis Cell Signaling & Oncology FLT3 VEGFR PDGFR c-KIT RTK class III and IV; EC 2.7.10.1 PDGFR, c-KIT and VEGFR tyrosine kinase inhibitor Chemical name 1-(4-(3-amino-1H-indazol-4-yl)phenyl)-3-(2-fluoro-5-methylphenyl)urea Parent CAS No. [796967-16-3] Order Size Unit Price Stock 5 mg €85.00 In Stock

產(chǎn)品價格

現(xiàn)貨詢價，電話：010-67529703

產(chǎn)品規(guī)格

產(chǎn)品品牌

axonmedchem

產(chǎn)品概述

產(chǎn)品詳情

ABT 869 - Linifanib

Based on 16 reference(s) in Google Scholar 9 10 16

Axon 1638

CAS [796967-16-3]

MF C21H18FN5O
MW 375.40

Purity: 99%
Soluble in DMSO

ABT 869

Description

A multi-targeted receptor tyrosine kinase (RTK) inhibitor, targeting VEGRFs, PDGFRs, Fms-like tyrosine kinase-3 and c-KIT. In cellular assays ABT869 inhibits RTK phosphorylation (IC50 = 2, 4, and 7 nM for PDGFR-β, KDR, and CSF-1R, respectively) and VEGF-stimulated proliferation (IC50 = 0.2 nM for human endothelial cells)

DH Albert et al. Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor. Mol. Cancer Ther. 2006, 5, 995-1006.

J Zhou et al. ABT-869, a promising multi-targeted tyrosine kinase inhibitor: from bench to bedside. J. Hematol. Oncol. 2009, 2, 33.

AK Ikeda et al. ABT-869 inhibits the proliferation of Ewing Sarcoma cells and suppresses platelet-derived growth factor receptor beta and c-KIT signaling pathways. Mol. Cancer Ther. 2010, 9(3), 653-60.

Certificate of Analysis
Material Safety Data Sheet

Angiogenesis Cell Signaling & Oncology FLT3 VEGFR PDGFR c-KIT RTK class III and IV; EC 2.7.10.1

PDGFR, c-KIT and VEGFR tyrosine kinase inhibitor

Chemical name

1-(4-(3-amino-1H-indazol-4-yl)phenyl)-3-(2-fluoro-5-methylphenyl)urea

Parent CAS No.

[796967-16-3]

產(chǎn)品資料

<button id="eiezk"><video id="eiezk"></video></button>